Cisplatin and Platinum-Based Chemotherapeutics: Molecular Mechanisms, Clinical Applications, and Emerging Strategies to Overcome Resistance
Keywords:
Cisplatin, platinum-based drugs, DNA adducts, apoptosis, chemoresistance, nanotechnology, combination therapy, cancer chemotherapyAbstract
For nearly half a century, cisplatin has stood as both a beacon of hope and a testament to the enduring struggle against cancer. Discovered serendipitously in the 1960s and granted FDA approval in 1978, this small platinum molecule transformed testicular cancer from a death sentence into a largely curable disease—saving countless young lives and reshaping the landscape of oncology. Yet behind this triumph lies a profound paradox: the very compound that brings healing also inflicts suffering. In response, science has not stood still. Next-generation analogs—carboplatin, oxaliplatin, nedaplatin, lobaplatin—have emerged with gentler toxic profiles, each carrying the legacy of their predecessor while seeking to soften its blows. Nanotechnology wraps the drug in protective carriers, guiding it toward tumors like a letter with a specific address. Combination therapies pair platinum with molecular partners—PI3K inhibitors, PARP inhibitors, immune checkpoint blockers—creating synergies that outsmart resistance. Epigenetic modulators and natural compounds, from curcumin to resveratrol, offer gentler hands to sensitize resistant cells. This review journeys through the molecular soul of cisplatin—from its chemical awakening in aqueous solutions, through its cellular travels and nuclear battles, to the clinical theaters where it saves and harms. We examine the mechanisms that make it work, the resistances that make it fail, and the innovations that seek to honor its legacy while transcending its limitations. For in the end, cisplatin is more than a drug; it is a chapter in humanity's ongoing dialogue with disease—a reminder that even our most powerful medicines carry the weight of compromise, and that the future of cancer care lies not in abandoning such tools, but in refining them with wisdom, precision, and ever-deepening compassion.
References
[1] B. Rosenberg, L. VanCamp, J. E. Trosko, and V. H. Mansour, "Platinum compounds: A new class of potent antitumour agents," Nature, vol. 222, no. 5191, pp. 385–386, 1969.
[2] L. Kelland, "The resurgence of platinum-based cancer chemotherapy," Nature Reviews Cancer, vol. 7, no. 8, pp. 573–584, 2007.
[3] S. Dasari and P. B. Tchounwou, "Cisplatin in cancer therapy: Molecular mechanisms of action," European Journal of Pharmacology, vol. 740, pp. 364–378, 2014.
[4] T. Boulikas and M. Vougiouka, "Cisplatin and platinum drugs at the molecular level," Oncology Reports, vol. 10, no. 6, pp. 1663–1682, 2003.
[5] L. Galluzzi et al., "Molecular mechanisms of cisplatin resistance," Oncogene, vol. 31, no. 15, pp. 1869–1883, 2012.
[6] E. Wong and C. M. Giandomenico, "Current status of platinum-based antitumor drugs," Chemical Reviews, vol. 99, no. 9, pp. 2451–2466, 1999.
[7] E. R. Jamieson and S. J. Lippard, "Structure, recognition, and processing of cisplatin-DNA adducts," Chemical Reviews, vol. 99, no. 9, pp. 2467–2498, 1999.
[8] R. A. Alderden, M. D. Hall, and T. W. Hambley, "The discovery and development of cisplatin," Journal of Chemical Education, vol. 83, no. 5, p. 728, 2006.
[9] F. Legendre, V. Bas, J. Kozelka, and J. C. Chottard, "A complete kinetic study of GG versus AG platination suggests that the doubly aquated derivatives of cisplatin are the actual DNA binding species," Chemistry – A European Journal, vol. 6, no. 11, pp. 2002–2010, 2000.
[10] M. D. Hall, M. Okabe, D. W. Shen, X. J. Liang, and M. M. Gottesman, "The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy," Annual Review of Pharmacology and Toxicology, vol. 48, pp. 495–535, 2008.
[11] T. Ishikawa and F. Ali-Osman, "Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells: Molecular characterization of glutathione-platinum complex and its biological significance," Journal of Biological Chemistry, vol. 268, no. 27, pp. 20116–20125, 1993.
[12] A. K. Holzer, B. H. Manorek, and S. B. Howell, "Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin," Molecular Pharmacology, vol. 70, no. 4, pp. 1390–1394, 2006.
[13] G. Ciarimboli et al., "Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2," American Journal of Pathology, vol. 167, no. 6, pp. 1477–1484, 2005.
[14] Y. Guo et al., "The platinum transporter ATP7B contributes to cisplatin resistance in human ovarian carcinoma cells," Molecular Pharmacology, vol. 95, no. 6, pp. 624–633, 2019.
[15] K. Katano et al., "Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper," Cancer Research, vol. 62, no. 22, pp. 6559–6565, 2002.
[16] J. König et al., "Expression and localization of human multidrug resistance protein (ABCC) family members in human kidney," Drug Metabolism and Disposition, vol. 33, no. 5, pp. 637–645, 2005.
[17] F. Coste et al., "Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 Å resolution: Hydration at the platinated site," Nucleic Acids Research, vol. 27, no. 8, pp. 1837–1846, 1999.
[18] Y. Jung and S. J. Lippard, "Direct cellular responses to platinum-induced DNA damage," Chemical Reviews, vol. 107, no. 5, pp. 1387–1407, 2007.
[19] E. E. Trimmer and J. M. Essigmann, "Cisplatin," Essays in Biochemistry, vol. 34, pp. 191–211, 1999.
[20] Y. Shiloh, "ATM and related protein kinases: Safeguarding genome integrity," Nature Reviews Cancer, vol. 3, no. 3, pp. 155–168, 2003.
[21] K. H. Vousden and C. Prives, "Blinded by the light: The growing complexity of p53," Cell, vol. 137, no. 3, pp. 413–431, 2009.
[22] Z. H. Siddik, "Cisplatin mode of cytotoxic action and molecular basis of resistance," Oncogene, vol. 22, no. 47, pp. 7265–7279, 2003.
[23] J. M. Adams and S. Cory, "The Bcl-2 apoptotic switch in cancer development and therapy," Oncogene, vol. 26, no. 9, pp. 1324–1337, 2007.
[24] D. R. Green and G. Kroemer, "Cytoplasmic functions of the tumour suppressor p53," Nature, vol. 458, no. 7242, pp. 1127–1130, 2009.
[25] S. Fulda and K. M. Debatin, "Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy," Oncogene, vol. 25, no. 34, pp. 4798–4811, 2006.
[26] J. A. McCubrey et al., "Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance," Biochimica et Biophysica Acta, vol. 1773, no. 8, pp. 1263–1284, 2007.
[27] R. J. Davis, "Signal transduction by the JNK group of MAP kinases," Cell, vol. 103, no. 2, pp. 239–252, 2000.
[28] A. Cuadrado et al., "A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis," EMBO Journal, vol. 26, no. 7, pp. 1807–1819, 2007.
[29] J. Hayakawa et al., "Inhibition of BAD phosphorylation either at serine112 via extracellular signal-regulated protein kinase cascade or at serine136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin," Cancer Research, vol. 60, no. 21, pp. 5988–5994, 2000.
[30] S. N. Westin et al., "Carboplatin and paclitaxel with or without bevacizumab in newly diagnosed ovarian cancer," New England Journal of Medicine, vol. 370, no. 26, pp. 2473–2474, 2014.
[31] H. Kasiganesan and G. L. Wright, "Cisplatin-induced oxidative stress stimulates renal Fas ligand expression," Pharmacological Research, vol. 52, no. 5, pp. 392–399, 2005.
[32] C. Tsangaris et al., "Cisplatin-induced oxidative stress and mitochondrial dysfunction in human keratinocytes," Toxicology in Vitro, vol. 58, pp. 59–66, 2019.
[33] Q. Ma, "Role of Nrf2 in oxidative stress and toxicity," Annual Review of Pharmacology and Toxicology, vol. 53, pp. 401–426, 2013.
[34] A. Mandic et al., "Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling," Journal of Biological Chemistry, vol. 278, no. 11, pp. 9100–9106, 2003.
[35] M. Wang and R. J. Kaufman, "The impact of the endoplasmic reticulum protein-folding environment on cancer development," Nature Reviews Cancer, vol. 14, no. 9, pp. 581–597, 2014.
[36] L. H. Einhorn, "Curing metastatic testicular cancer," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 7, pp. 4592–4595, 2002.
[37] A. du Bois et al., "Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of three prospectively randomized phase III multicenter trials," Cancer, vol. 115, no. 6, pp. 1234–1244, 2009.
[38] D. K. Armstrong et al., "Intraperitoneal cisplatin and paclitaxel in ovarian cancer," New England Journal of Medicine, vol. 354, no. 1, pp. 34–43, 2006.
[39] J. H. Schiller et al., "Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer," New England Journal of Medicine, vol. 346, no. 2, pp. 92–98, 2002.
[40] D. J. Stewart, "Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer," Critical Reviews in Oncology/Hematology, vol. 75, no. 3, pp. 173–234, 2010.
[41] J. P. Pignon, A. le Maître, E. Maillard, and J. Bourhis, "Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients," Radiotherapy and Oncology, vol. 92, no. 1, pp. 4–14, 2009.
[42] H. B. Grossman et al., "Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer," New England Journal of Medicine, vol. 349, no. 9, pp. 859–866, 2003.
[43] A. H. Calvert et al., "Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II," Cancer Chemotherapy and Pharmacology, vol. 9, no. 3, pp. 140–147, 1982.
[44] D. I. Jodrell et al., "Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer," Journal of Clinical Oncology, vol. 10, no. 3, pp. 520–528, 1992.
[45] A. de Gramont et al., "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer," Journal of Clinical Oncology, vol. 18, no. 16, pp. 2938–2947, 2000.
[46] M. Ishibashi et al., "Phase II study of nedaplatin (254-S) and 5-fluorouracil in patients with squamous cell carcinoma of the head and neck," Japanese Journal of Clinical Oncology, vol. 33, no. 11, pp. 548–552, 2003.
[47] B. Peng et al., "Lobaplatin inhibits growth of gastric cancer cells by inducing apoptosis," World Journal of Gastroenterology, vol. 20, no. 46, pp. 17426–17433, 2014.
[48] G. Samimi et al., "Modulation of cisplatin sensitivity by the interaction between human copper transporter 1 (hCTR1) and filamin A," Proceedings of the American Association for Cancer Research, vol. 44, Abstract 2754, 2003.
[49] M. T. Kuo et al., "The roles of copper transporters in cisplatin resistance," Cancer Metastasis Reviews, vol. 26, no. 1, pp. 71–83, 2007.
[50] M. Dabholkar et al., "ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients," Journal of the National Cancer Institute, vol. 84, no. 19, pp. 1512–1517, 1992.
[51] D. Fink et al., "The role of DNA mismatch repair in platinum drug resistance," Cancer Research, vol. 56, no. 21, pp. 4881–4886, 1996.
[52] A. M. Haslehurst et al., "EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer," BMC Cancer, vol. 12, Art. no. 91, 2012.
[53] X. Chen and E. Song, "Turning foes to friends: Targeting cancer-associated fibroblasts," Nature Reviews Drug Discovery, vol. 18, no. 2, pp. 99–115, 2019.
[54] M. Le Gallo et al., "Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes," Nature Genetics, vol. 44, no. 12, pp. 1310–1315, 2012.
[55] M. V. Liberti and J. W. Locasale, "The Warburg effect: How does it benefit cancer cells?," Trends in Biochemical Sciences, vol. 41, no. 3, pp. 211–218, 2016.
[56] S. Fulda, "Evasion of apoptosis as a cellular stress response in cancer," International Journal of Cell Biology, vol. 2010, Art. no. 370835, 2010.
[57] R. Garzon, G. Marcucci, and C. M. Croce, "Targeting microRNAs in cancer: Rationale, strategies and challenges," Nature Reviews Drug Discovery, vol. 9, no. 10, pp. 775–789, 2010.
[58] G. P. Stathopoulos et al., "Liposomal cisplatin combined with gemcitabine in patients with advanced non-small cell lung cancer," Oncology Reports, vol. 25, no. 1, pp. 259–265, 2011.
[59] S. Dhar, F. X. Gu, R. Langer, O. C. Farokhzad, and S. J. Lippard, "Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 45, pp. 17356–17361, 2008.
[60] S. M. Maira et al., "Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity," Molecular Cancer Therapeutics, vol. 7, no. 7, pp. 1851–1863, 2008.
[61] L. Gandhi et al., "Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer," New England Journal of Medicine, vol. 378, no. 22, pp. 2078–2092, 2018.
[62] D. Buglio et al., "Vorinostat inhibits MAPK signaling and restores cisplatin sensitivity in resistant non-small cell lung carcinoma cells," Proceedings of the American Association for Cancer Research, vol. 49, Abstract 2996, 2008.
[63] D. J. Stewart, "Wnt signaling pathway in non-small cell lung cancer," Journal of the National Cancer Institute, vol. 106, no. 1, Art. no. djt356, 2014.
[64] X. Yao, K. Panichpisal, N. Kurtzman, and K. Nugent, "Cisplatin nephrotoxicity: A review," American Journal of the Medical Sciences, vol. 334, no. 2, pp. 115–124, 2007.
[65] G. Kemp et al., "Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized controlled trial in patients with advanced ovarian cancer," Journal of Clinical Oncology, vol. 14, no. 7, pp. 2101–2112, 1996.
[66] E. Gamelin, L. Gamelin, L. Bossi, and S. Quasthoff, "Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures," Seminars in Oncology, vol. 29, no. 5, Suppl. 15, pp. 21–33, 2002.
[67] P. R. Brock et al., "Sodium thiosulfate for protection from cisplatin-induced hearing loss," New England Journal of Medicine, vol. 378, no. 25, pp. 2376–2385, 2018.
[68] P. J. Hesketh et al., "Antiemetics: American Society of Clinical Oncology clinical practice guideline update," Journal of Clinical Oncology, vol. 35, no. 28, pp. 3240–3261, 2017.
[69] D. S. Alberts et al., "Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer," Journal of Clinical Oncology, vol. 10, no. 5, pp. 706–717, 1992.
